Hepatitis B Immune Globulin (HBIG)
A to Z Drug Facts
Hepatitis B Immune Globulin (HBIG) |
(hep-uh-TIGHT-iss) |
BayHep B |
Injection |
217 IU/mL |
Nabi HB |
Injection |
312 IU/mL |
Bayhep B |
Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Pregnancy: Category C. Lactation: Undetermined.
PATIENT CARE CONSIDERATIONS |
|
Books@Ovid
Copyright © 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts